An Update on Sunitinib as First-Line Therapy for Metastatic RCC

Page 1

Visit us online at www.physweekly.com

Special Issue 2009

An Update on Sunitinib as FirstLine Therapy for Metastatic RCC Data demonstrate that treatment-na誰ve patients with metastatic renal-cell carcinoma, or mRCC, who received sunitinib malate had longer progressionfree survival and higher response rates than those receiving interferon alfa with a median overall survival of 2 years.

Kidney cancer accounts for approximately 2% of all new cancer cases throughout the world.1 According to the National Cancer Institute, there were about 54,390 new cases of kidney cancer in the United States in 2008.2 Renal cell carcinoma (RCC), which arises primarily from the proximal tubular epithelium, accounts for approximately 85% of all kidney cancers; the remainder consists of renal pelvis cancer and other rare malignancies. Many patients with RCC are asymptomatic and cannot be palpated until relatively late in the

www.physweekly.com

|1


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.